Class of Stock [Axis]
American Depositary Shares, each representing 80,000 Ordinary Shares, par value $0.000000005 per share [Member]
Ordinary Shares, $0.000000005 par value per share [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Capital Units [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Deferred Compensation, Share-Based Payments [Member]
Title and Position [Axis]
ADS [Member]
Statistical Measurement [Axis]
Maximum [Member]
Minimum [Member]
Intangible Asset, Indefinite-Lived, Class [Axis]
Gross Carrying Amount [Member]
Intangible Asset, Finite-Lived, Class [Axis]
AKTX-101 [Member]
Cumulative Impairment Charge [Member]
Net Book Value [Member]
PHP-303 [Member]
Debt Instrument [Axis]
September 2024 Note Payable [Member]
April 2023 Convertible Notes [Member]
April 2023 Convertible Notes and Warrants Amendment [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Letter Agreement [Member]
April, 2023 Peak Bio Convertible Noteholder Warrants [Member]
Measurement Input Type [Axis]
Measurement Input, Share Price [Member]
Measurement Input, Price Volatility [Member]
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input, Expected Term [Member]
April, 2023 Convertible Note [Member]
ADR [Member]
Ordinary Shares [Member]
ELOC Purchase Agreement [Member]
Legal Entity [Axis]
White Lion Capital LLC [Member]
Measurement Input, Discount Rate [Member]
Sale of Stock [Axis]
Private Placement [Member]
Class of Warrant or Right [Axis]
Series G Warrants [Member]
Series G Warrant [Member]
2025 Registered Direct Offering [Member]
December2025 Investor Prefunded Warrant [Member]
April 2025 Investor Prefunded Warrants [Member]
October 2023 Investor Prefunded [Member]
December 2025 Series G Investor Warrants [Member]
December 2025 Note Exchange Warrants [Member]
December 2025 Placement Agent Warrants [Member]
April 2023 Peak Bio Warrants [Member]
March 2025 Series A Investor Warrants [Member]
March 2025 Investor Warrants [Member]
April 2025 Series A Investor Warrants [Member]
April 2025 Investor Warrants [Member]
October 2025 Series E Investor Warrants [Member]
October 2025 Series F Investor Warrants [Member]
October 2025 Placement Agent Warrants [Member]
May 2024 Investor Warrants [Member]
March 2024 Placement Agent Warrants [Member]
May 2024 Placement Agent Warrants [Member]
November 2024 Investor Warrants [Member]
October 2023 Placement Agent Warrants [Member]
March 2022 Investor Warrants [Member]
March 2022 Placement Agent Warrants [Member]
December 2021 Investor Warrants [Member]
December 2021 Placement Agent Warrants [Member]
July 2021 Placement Agent Warrants [Member]
April 2023 Peak Bio Warrants [Member]
September 2022 Series B Investor Warrants [Member]
November 2022 Peak Bio Warrants [Member]
Warrant [Member]
Revision of Prior Period [Axis]
Previously Reported [Member]
Plan Name [Axis]
Equity Incentive Plan 2014 Equity Incentive Plan 2023 And Peak Bio 2022 Long Term Incentive Plan [Member]
Award Type [Axis]
Restricted Stock Units (RSUs) [Member]
Performance Shares [Member]
Unvested Stock Option [Member]
Product and Service [Axis]
Research and Development [Member]
General and Administrative [Member]
Measurement Frequency [Axis]
Fair Value, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
September 2022 Series B Warrants [Member]
Total Warrant Liability [Member]
Derivative Liability [Member]
November 2022 Warrants [Member]
April 2023 Warrants [Member]
Measurement Input, Exercise Price [Member]
Measurement Input, Expected Dividend Rate [Member]
Antidilutive Securities [Axis]
Share-Based Payment Arrangement, Option [Member]
Convertible Debt Securities [Member]
Impairment Loss on Other Intangible Assets [Member]
Other Commitments [Axis]
Expected Current Year Loss and Historical Loss [Member]
ADC Preclinical Development [Member]
Segments [Axis]
Significant Segment Expense Category [Member]
HSCT-TMA (AK901) Clinical Program [Member]
Chemistry, Manufacturing and Control [Member]
Other External Development Expense Income [Member]
Internal and Other Research and Development Expense [Member]
Related and Nonrelated Parties [Axis]
Related Party [Member]
Loss Contingency Nature [Axis]
Withdrawal from Multiemployer Defined Benefit Plan [Member]
Retirement Plan Sponsor Location [Axis]
Foreign Plan [Member]
Business Combination [Axis]
Bayer Acquisition Agreement [Member]
Settlement Agreement [Member]
Statement [Table]
Statement [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash
Restricted cash
Prepaid expenses
Other current assets
Total current assets
Goodwill
Other intangible assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued expenses
Convertible notes, net
Notes payable, net
Warrant liabilities
Other current liabilities
Total current liabilities
Derivative liability
Other non-current liabilities
Deferred tax liability
Total liabilities
Commitments and contingencies (Note 13)
Shareholders’ equity:
Authorized: 761,963,201,733 ordinary shares at March 31, 2026, and December 31, 2025; issued and outstanding: 91,567,009,533 and 90,536,879,533 ordinary shares at March 31, 2026, and December 31, 2025, respectively
Additional paid-in capital
Capital redemption reserve
Accumulated other comprehensive loss
Accumulated deficit
Total shareholders’ equity
Total liabilities and shareholders’ equity
Ordinary shares, par value
Ordinary shares, shares authorized
Ordinary shares, shares issued
Ordinary shares, shares outstanding
Income Statement [Abstract]
Operating expenses:
Research and development
General and administrative
Impairment loss on other intangible assets
Impairment loss on goodwill
Total operating expenses
Loss from operations
Other income (expense):
Interest expense
Gain on settlement of current liabilities
Change in fair value of warrant liabilities
Change in fair value of derivative liability
Foreign currency exchange gain (loss), net
Total other income (expense), net
Net loss before income taxes
Benefit from deferred income taxes
Net loss
Net loss per share - basic
Net loss per share - diluted
Weighted-average number of ordinary shares used in computing net loss per share - basic
Weighted-average number of ordinary shares used in computing net loss per share - diluted
Comprehensive loss:
Net loss
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment
Total other comprehensive income (loss), net of tax
Total comprehensive loss
Balance
Balance, shares
Issuance of share capital related to financing, net of issuance costs
Issuance of share capital related to financing, net of issuance costs, shares
Stock-based compensation
Foreign currency translation
Balance
Balance, shares
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES:
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Accretion of debt issuance costs on convertible notes payable
Gain on settlement of current liabilities
Change in fair value of warrant liabilities
Change in fair value of derivative liability
Deferred tax benefit
Unrealized foreign currency exchange gains
Change in assets and liabilities:
Prepaid expenses and other current assets
Accounts payable, accrued expenses and other current liabilities
Net cash used in operating activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares, net of issuance costs
Proceeds from deposits received for share subscriptions
Repayments of notes payable
Payments on short-term financing arrangement
Net cash provided by financing activities
Net change in cash
Cash and restricted cash at beginning of period
Cash and restricted cash at end of period
Components of cash and restricted cash
Cash
Restricted cash
Total cash and restricted cash
SUPPLEMENTAL DISCLOSURES OF NON-CASH ACTIVITIES:
Financing costs in accrued expenses
Financing costs for deposits received from share subscriptions in accounts payable
Issuance of share capital for settlement of related party debt
Short-term financing arrangement
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for interest
Cash paid for income taxes
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Rule 10b5-1 Arrangement Modified
Non-Rule 10b5-1 Arrangement Modified
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Management Third Party Engaged [Flag]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Material Cybersecurity Incident [Abstract]
Material Cybersecurity Incident Nature [Text Block]
Material Cybersecurity Incident Scope [Text Block]
Material Cybersecurity Incident Timing [Text Block]
Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]
Accounting Policies [Abstract]
Description of Business
Summary of Significant Accounting Policies
Intangible Asset, Goodwill and Other [Abstract]
Goodwill and Intangible Assets
Payables and Accruals [Abstract]
Convertible Notes and Notes Payable
Equity [Abstract]
Shareholders’ Equity
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation
Fair Value Disclosures [Abstract]
Fair Value Measurements
Earnings Per Share [Abstract]
Net Loss per Share
Income Tax Disclosure [Abstract]
Income Taxes
Segment Reporting [Abstract]
Segment Information
Related Party Transactions [Abstract]
Related Party Transactions
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Recent accounting pronouncements
Schedule of Other Intangible Assets
Summary of Accrued Expenses
Schedule of Summarizes the Outstanding Warrants
Schedule of Warrants Activity
Schedule of Stock Option Activity
Schedule of Weighted-average Assumptions and Fair Value of Share Options Granted
Schedule of RSU activity
Schedule of Stock-based Compensation Expense in Statements of Operations
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis
Schedule of Fair value on Recurring Basis using Unobservable Inputs
Schedule of Assumptions used for Fair Value Calculations of Warrants
Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share
Schedule of Significant Segment Expense Categories
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Accumulated deficit
Deferred shares
Deferred share price
Number of shares repurchased
Number of outstanding shares
Share price
Intangible Asset, Indefinite-Lived [Table]
Intangible Asset, Indefinite-Lived [Line Items]
Total other intangible assets
Intangible Asset, Excluding Goodwill, Impairment Loss
Goodwill impairment charge
Employee compensation and benefits
External research and development expenses
Professional and consulting fees
Other
Total accrued expenses
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Notes payable
Payment terms
Principal amount
Conversion price per share
Interest rate
Debt conversion original debt
Amortization of interest expense
Number of warrants
Ordinary shares issued
Change in fair value of warrants
Aggregate fair value
Expected term
Interest expenses
Accrued interest
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants ADSs
Weighted-Average Exercise Price
Liability-classified Warrants
Liability-classified Warrants
Total outstanding
Number of Warrants Outstanding Beginning Balance
Weighted Average Exercise Price Outstanding, Beginning Balance
Number of Warrants, Issued
Weighted-Average Exercise Price, Issued
Number of Warrants, Exercised
Weighted-Average Exercise Price, Exercised
Number of Warrants, Expired
Weighted-Average Exercise Price, Expired
Number of Warrants Outstanding Ending Balance
Weighted Average Exercise Price Outstanding, Ending Balance
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Number of shares authorized
Number of ordinary shares representing one ADS
Gross proceeds from issuance of ordinary shares
Trading percentage
Trading price discount percentage
Volume weighted average price
Trading percentage, thereafter
Ordinary shares issued
Exchange cap rate
Beneficial ownership limitation
Beneficial ownership limitation increased
Purchase commitment, description
Document fee
Derivative Liability, Fair Value of Collateral
Derivative Liability, Measurement Input
Aggregate ADSs issued
Warrants issued
Unit price
Common stock shares
Subscription amount
Aggregate gross proceeds
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, Options Outstanding
Weighted average exercise price, Outstanding at beginning
Weighted average remaining contractual life, Options outstanding
Aggregate intrinsic value, Options outstanding
Number of shares, Granted
Weighted average exercise price, Granted
Number of shares, Exercised
Weighted average exercise price, Exercised
Number of shares, Forfeited
Weighted average exercise price, Forfeited
Number of shares, Expired
Weighted average exercise price, Expired
Number of shares, Options Outstanding
Weighted average exercise price, Outstanding at ending
Aggregate intrinsic value, Options outstanding
Number of stock options exercisable shares
Weighted average exercise price, Exercisable
Weighted average remaining contractual term, Options exercisable
Aggregate intrinsic value, Options exercisable
Expected volatility
Risk-free interest rate
Expected dividend yield
Expected term (in years)
Number of ADSs nonvested shares, balance
Weighted average grant date fair value per share, Beginning
Number of ADSs nonvested shares, Granted
Weighted average grant date fair value per share, Granted
Number of ADSs nonvested shares, Forfeited
Weighted average grant date fair value per share, Forfeited
Number of ADSs nonvested shares, Vested
Weighted average grant date fair value per share, Vested
Number of ADSs nonvested shares, balance
Weighted average grant date fair value per share, Ending
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense
Weighted average grant date
Shares underlying vested
Fair value of time-based RSUs that vested
Aggregate of shares
Unrecognized compensation
Weighted average period
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Derivative liability - ELOC
Fair Value, off-Balance-Sheet Risk [Table]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Balance
Change in fair value of liability
Balance
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant outstanding input
Derivative liabilities
Derivative liability measurement input
Difference in derivative liabilities
Impairment charge
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total
Intangible Asset, Finite-Lived [Table]
Intangible Asset, Finite-Lived [Line Items]
Income tax expense
Unrecognized tax benefits
Segment Reporting [Table]
Segment Reporting [Line Items]
Internal and other research and development expense
General and administrative expense
Stock-based compensation expense
Other segment items
Number of Operating Segments
Number of reportable segments
Segment reporting description
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Amount due to related party
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Lease costs
Description of employee benefit plans
Operating expenses
Development and regulatory milestone committed payment amount
Acquisition Agreement incurred expenses
Discretionary Bonus
Ordinary Shares, $0.000000005 par value per share [Member]
American Depositary Shares, each representing 80,000 Ordinary Shares, par value $0.000000005 per share [Member]
Non Rule 10b51 Arr Modified Flag.
September 2024 Note Payable [Member]
April 2023 Convertible Notes [Member]
Warrant liabilities current.
Capital redemption reserve.
April Two Thousand Twenty Three Convertible Notes and Warrants Amendment Member.
Letter Agreement [Member]
April TwoThousand Twenty Three Peak Bio Convertible Noteholder Warrants Member.
April Two Thousand Twenty Three Convertible Note [Member]
Number of ordinary shares representing one american depositary share.
Ordinary Shares [Member]
ELOC Purchase Agreement Member.
White Lion Capital LLC Member.
Trading Price Percentage.
Trading price discount percentage.
Volume weighted average price.
Trading percentage, thereafter.
Gain on settlement of current liabilities.
Beneficial ownership limitation percentage.
Beneficial ownership limitation percentage increase.
Series G Warrants [Member]
Series G Warrant [Member]
Subscription amount.
2025 Registered Direct Offering [Member]
Class of warrant or right outstanding equity
December2025 Investor Prefunded Warrant [Member]
October 2023 Investor Prefunded [Member]
April 2025 Investor Prefunded Warrants [Member]
December 2025 Series G Investor Warrants [Member]
December 2025 Note Exchange Warrants [Member]
December 2025 Placement Agent Warrants [Member]
April 2023 Peak Bio Warrants [Member]
March 2025 Series A Investor Warrants [Member]
October 2025 Series E Investor Warrants [Member]
October 2025 Series F Investor Warrants [Member]
October 2025 Placement Agent Warrants [Member]
May 2024 Investor Warrants [Member]
March 2024 Placement Agent Warrants [Member]
May 2024 Placement Agent Warrants [Member]
November 2024 Investor Warrants [Member]
October 2023 Placement Agent Warrants [Member]
March 2022 Investor Warrants [Member]
March 2022 Placement Agent Warrants [Member]
December 2021 Investor Warrants [Member]
December 2021 Placement Agent Warrants [Member]
July 2021 Placement Agent Warrants [Member]
Class of warrant or right outstanding liability
September 2022 Series B Investor Warrants [Member]
November 2022 Peak Bio Warrants [Member]
Liabilityclassified warrants
April 2023 Peak Bio Warrants [Member]
April 2025 Series A Investor Warrants [Member]
April 2025 Investor Warrants [Member]
March 2025 Investor Warrants [Member]
Issuance of share capital for settlement of related party debt.
Schedule Of Warrants Activity [Text Block]
Weighted average exercise price outstanding warrants
Weighted average exercise price issued warrants.
Weighted average exercise price expired warrants
Weighted average exercise price exercised warrants.
Equity Incentive Plan 2014 Equity Incentive Plan 2023 And Peak Bio 2022 Long Term Incentive Plan [Member]
Proceeds from issuance of shares net of issuance costs.
Financing costs in accrued expenses.
Financing costs for deposits received from share subscriptions in accounts payable.
Shortterm financing arrangement.
Share based compensation arrangement by share based payment award equity instruments other than options underlying vested in period
Unvested Stock Option [Member]
September 2022 Series B Warrants [Member]
Derivative Liability [Member]
Disclosure Of Fair Value Assumptions Of Warrants [Table Text Block]
November 2022 Warrants [Member]
April 2023 Warrants [Member]
ADS [Member]
Accrued external research and development expenses.
Amount due to related party.
Bayer Acquisition Agreement [Member]
Settlement Agreement [Member]
Internal and Other Research and Development Expense [Member]
Significant Segment Expense Category [Member]
Other External Development Expense Income [Member]
Chemistry, Manufacturing and Control [Member]
HSCT-TMA (AK901) Clinical Program [Member]
Accretion of debt issuance costs on convertible notes payable.
Rule 10b51 Arr Modified Flag.
Research and Development [Member]
General and Administrative [Member]
ADC Preclinical Development [Member]
AKTX-101 [Member]
PHP-303 [Member]
Total Warrant Liability [Member]
Gross Carrying Amount [Member]
Cumulative Impairment Charge [Member]
Net Book Value [Member]
Impairment Loss on Other Intangible Assets [Member]
Expected Current Year Loss and Historical Loss [Member]
April 2023 Peak Bio Warrants [Member] [Default Label]
Assets, Current
Assets
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Income (Loss)
Interest Expense, Nonoperating
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Income Tax Expense (Benefit)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Share-Based Payment Arrangement, Noncash Expense
Gain (Loss), Foreign Currency Transaction, before Tax
Increase (Decrease) in Prepaid Expenses, Other
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Repayments of Short-Term Debt
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Cash [Default Label]
Restricted Cash and Cash Equivalent
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
LiabilityclassifiedWarrants
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
WeightedAverageExercisePriceOutstandingWarrants
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Financial Liabilities Fair Value Disclosure
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value